Lung function after allogeneic bone marrow transplantation for leukaemia or lymphoma

Area of Science:

• Pediatric Oncology
• Pulmonology
• Hematology

Background:

• Allogeneic bone marrow transplantation (BMT) is a curative treatment for childhood leukaemia and lymphoma.
• Conditioning regimens often involve chemotherapy and total body irradiation (TBI), which can have long-term toxicities.
• Pulmonary complications after BMT can significantly impact patient outcomes and quality of life.

Purpose of the Study:

• To assess long-term pulmonary function in survivors of childhood leukaemia or lymphoma treated with cyclophosphamide and TBI followed by allogeneic BMT.
• To determine if children are particularly vulnerable to pulmonary damage after this treatment protocol.

Main Methods:

• Longitudinal analysis of pulmonary function tests in 25 survivors of childhood leukaemia/lymphoma.
• Data collected over 4-13 years post-allogeneic bone marrow transplantation.
• Assessment included transfer factor, lung volumes, and forced expiratory ratios.

Main Results:

• Patients exhibited significantly reduced transfer factor, total lung capacity, and forced vital capacity at a median of 8 years post-transplant.
• An increased ratio of forced expiratory volume in one second to forced vital capacity was observed.
• No patients developed chronic graft-versus-host disease or reported pulmonary symptoms, indicating subclinical disease.

Conclusions:

• Survivors of childhood leukaemia/lymphoma treated with cyclophosphamide and TBI followed by allogeneic BMT develop subclinical restrictive pulmonary disease.
• Pulmonary function deficits persist long-term after treatment, highlighting the need for ongoing monitoring.
• Children may experience lasting pulmonary impairment following intensive BMT conditioning.